Antibody-drug conjugates are chemotherapy with a guidance system. A potent cytotoxic drug — too toxic to give on its own — is chemically tethered to an antibody that recognises a protein on the cancer cell surface. The antibody delivers the payload directly into the tumour cell, sparing healthy tissue. Each ADC is defined by three things: the target it homes in on, the payload it carries, and the linker holding them together.
Class descriptions are written by the Priya Life Science editorial team. Individual drug pages combine that summary with live label, approval, manufacturer and shortage data from the U.S. FDA via the openFDA API. This page is general information and is not medical advice — it is not exhaustive, drugs within a class are not automatically interchangeable, and approvals and brand names differ between the US, EU/Ireland (EMA/HPRA) and other regions. Always consult the official prescribing information and your clinician or pharmacist. Related: Drug Shortages Tracker · FDA Approvals · All drug comparisons